Winfield Associates’s Puma Biotechnology PBYI Stock Holding History

Winfield Associates’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10	Closed	–	–	753
2016 Q1	$0	Buy	+10	New	+$452	﹤0.01%	706

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Winfield Associates's PBYI Position: Q2 2016 in Review

Winfield Associates sold out of Puma Biotechnology (PBYI) in Q2 2016, closing a stake of 10 shares.

Winfield Associates first reported a position in PBYI in Q1 2016 and held it in 1 quarter. The position peaked at $0 in Q1 2016. 110 funds tracked by Wall St. Rank hold PBYI as of Q2 2016.

Winfield Associates reported no remaining Puma Biotechnology position as of Q2 2016 after selling out during the quarter.
Winfield Associates sold 10 Puma Biotechnology shares in Q2 2016.
Winfield Associates first reported a position in Puma Biotechnology in Q1 2016 and held it in 1 quarter.
Winfield Associates's Puma Biotechnology position peaked at $0 in Q1 2016.
110 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2016.

Based on Winfield Associates's 13F filing for Q2 2016, filed 15 Aug 2016.